Effect Of Semaglutide In Coronary Atheroma Plaque

Inclusion Criteria: * Men and women ≥35 and ≤ 65 years * Absence of previous history of clinical cardiovascular events * Subjects already taking therapy for diabetes on stable doses for 3 months or more. * Subjects must have HbA1c at the initial screening visit between 8 and 10% * Coronary CT performed less than 3 months before starting study medication Exclusion Criteria: * Clinically significant heart disease * New York Heart Association (NYHA) class \>II * Known stroke or transient ischemic accident * Uncontrolled hypertension at randomization, defined as a resting systolic blood pressure of 180 mm Hg at rest * Personal or family history of hereditary muscular disorders * Fasting triglyceride level \> 250 mg/dL at screening * Type 1 diabetes * Known thyroid disease or subject taking thyroid replacement therapy * Estimated glomerular filtration rate \< 60 ml/min/1.73m2 * History of malignancy * Known major active infection, or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction * Baseline coronary CT does not meet Core Lab technical standards * Cardiac rhythm different to normal sinus rhythm. * Female subjects cannot be pregnant or breastfeeding, planning to become pregnant or planning to breastfeed during the entire study * Premenopausal females of childbearing potential must be willing to use an acceptable method(s) of birth control during treatment and for an additional 15 weeks after the end of treatment